C stasis may be caused by deficiencies or abnormalities in plasma factors, such as von Willebrand factor (vWF)' or fibrinogen: or to intrinsic defects of platelet adhesion, aggregation, or ~ecretion.3,~ Platelet adhesion may be impaired in Bernard-Soulier syndrome because of the absence of the membrane glycoprotein (GP) Ib-IX complex, which binds v W F or in congenital deficiencies of the membrane GPs Ia-IIa complex5 or GP which bind collagen. Platelet aggregation induced by any agonist is absent in Glanzmann's thrombasthenia because of quantitative or qualitative abnormalities of the GP IIb-IIIa complex, which serves as receptor for adhesive glycoproteins, such as fibrinogen, vWF, fibronectin, and ~itronectin.~ Platelet secretion defects are heterogeneous, including diminished content of dense-granule constituents (delta-storage pool deficiency) or of combinations of diminished dense-and a-granule contents,s altered arachidonic acid metabolism? impaired responses to weak agonists9 and other abnormalities,3 and also result in impaired, although not absent, platelet aggregation in response to a variety of agonists. The impaired platelet aggregation occurring in platelet secretion or activation defects is characterized by a normal or partially impaired primary wave of aggregation induced by weak agonists but absent secondary wave of aggregation,3,4,8,9 and is mainly caused by the loss of the potentiating effect of released adenosine diphosphate (ADP) on platelet aggregation and fibrinogen binding4 Other intrinsic abnormalities of platelet function have been described, characterized by impaired responses to specific agonists, such as epinephrine,1° platelet-activating factor (PAFacether)," or the divalent cation ionophore A23187,12 with no aggregation defect to other agonists.
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In the present study we report a congenital defect of platelet function that is caused by selective impairment of platelet responses to ADP, and results in a severely impaired primary wave of aggregation in response to exogenous ADP and defective aggregation to a variety of release-inducing agonists. 
MATERIALS AND METHODS

Patient
The propositus, V.R., is a white man who was born in 1937 in Southern Italy. His parents were first cousins and never suffered from a bleeding tendency. The patient has a lifelong history of mucosal bleeding (especially nose bleeds) and easy bruising. He was transfused with several units of blood products after having suffered from accidental burns to the chest and upper limbs at age 18, and after two episodes of diffuse bleeding from the gastric mucosa at ages 45 and 50. His bleeding diathesis was exacerbated by the ingestion of nonsteroidal anti-inflammatory drugs. In 1978 a defect of the platelet release reaction was diagnosed at another hospital, but was not further characterized. He came to our hospital in 1986. His platelet count, activated partial thromboplastin time, prothrombin time, vWF:antigen, and ristocetin cofactor activity were within normal limits. The template bleeding time (Simplate 11; General Diagnostics, Morris Plains, NJ) was 22, 18, and 24 minutes in three different determinations (normal range 2 to 8 minutes). Ristocetin-induced platelet agglutination was normal. The platelet contents of serotonin, ADP, adenosine triphosphate (ATP), P-thromboglobulin, and platelet factor 4 were within The only relatives of the patient available for study were his brother and sister, who were asymptomatic and had normal bleeding times.
Materials
Carrier-free sodium iodide (1251), I4C-serotonin (5-hydroxytryptamine-3'-14C-creatinine sulfate, 57.5 mciimmol), and 14C-ADP (55 Ci/mol) were obtained from Amersham International ( h e rsham, Buckinghamshire, UK). [2-3H]-adenosine 5'-diphosphate (27.3 and 25.4 Ci/mmol) was from New England Nuclear (Florence, Italy). Apyrase, prepared from potatoes by the method of Molnar and Lorand,I3 was a kind gift of Drs J.F. Mustard and R.L.
Kinlough-Rathbone (McMaster University, Hamilton, Ontario, Canada). The activity of the preparation was such that the enzyme (1 pL/mL) converted 0.25 pmol/L ATP to adenosine monophosphate (AMP) within 120 seconds at 37°C. Bovine serum albumin, ATP, ADP, epinephrine, prostaglandin El (PGEI), thrombin, the thromhoxane/prostaglandin endoperoxide analogue 9,ll-dideoxy-11,9-epoxymethano-prostaglandin Fz (U46619), arachidonic acid, creatine phosphate (CP), creatine phosphokinase (CPK), indomethacin, chymotrypsin, imipramine, and collagen were from Sigma (St Louis, MO). Reptilase and adenosine-5'-0-(2-thiodiphosphate) Trilitium salt (ADP-P-S) were from Boehringer (Mannheim, Germany). Hirudin was from Pentapharma (Basel, Switzerland). Fura 2/AM was from Calbiochem (La Jolla, CA). The anti-GPIIb/ IIIa monoclonal antibodies (MoAbs) 10E5 and 7E3 were generous gifts of Dr B. Coller (SUNY, Stony Brook, NY). The tissue solubilizer NCS and the nonaqueous counting scintillant OCS were from Amersham International. The ACD-buffer (pH 6.5) used in the preparation of formalin-fixed platelets had the following composition: 5.5 mmol/L dextrose, 128 mmol/L NaCI, 4.26 mmol/L NaH2P04, 7.46 mmol/L Na2HP04, 4.77 mmol/L Na3 citrate, 2.3.5 mmol/L citric acid. All chemicals were of reagent grade or better.
Preparation of Platelet-rich Plasma (PRP) and Washed Platelet Suspensions
Citrated PRP was prepared as describedI4; the final platelet count was adjusted to 3 x lO"/L. For studies of platelet aggregation and binding of 14C-ADP, 1251-labeled fibrinogen, IxI-vWF, 1251-10ES, and '"1-7E3, platelets were washed according to the method described by Mustard et all5 and suspended in Tyrode buffer containing 0.35% albumin, 0.1% dextrose, and apyrase (1 pL/mL). For experiments in which the release reaction was studied, the platelets were labeled in the first washing fluid with 14C-5HT (0.1 pCi/mL); imipramine (2 pmol/L) was added to final platelet suspension to avoid the reuptake of released 14C-5HT. In some experiments, platelets were incubated with 8 U/mL chymotrypsin at 37°C for 30 minutes during the first wash. For studies of 14C-ADP binding, apyrase was omitted from the final suspension.
For studies of [2-3H]ADP binding to formalin fked platelets, platelets were prepared as described by Jefferson et al,I6 with slight modifications. Briefly, PRP obtained from blood anticoagulated with acid-citrate-dextrose (ACD) was treated with 1 pmol/L PGEl and 4 mmol/L EDTA. The pH was adjusted to 6.5 with citric acid, and the PRP was centrifuged at room temperature at 1,400g for 10 minutes. The platelet pellet was then resuspended in 20 mL ACD-buffer containing 1 pmol/L PGEI. Platelets were then centrifuged at SOOg for 3 minutes and resuspended in 20 mL ACD-buffer. These resuspension and centrifugation steps were repeated three times, after which platelets were resuspended in 5 mL ACD-buffer, to which 45 mL of 4% paraformaldehyde dissolved in phosphate-buffered saline (PBS) was added. Platelets were left at 4°C for 48 hours to fix, and then centrifuged (80% for 3 minutes), washed three times in 5 mL PBS, and resuspended in Tyrode buffer. The platelet count was adjusted to 5 x lO"/L, and the suspension was immediately used for binding studies.
Iodination of Fibrinogen, vWF, and the Anti-GPZZblIZIa MoAbs 1 OE5 and 7E3
Human fibrinogen was purified from citrated plasma according to the method described by Kazal et a1.I' vWF was purified as previously described.l8 Fibrinogen, vWF, 10E5, and 7E3 were labeled with lZ5I by the iodogen method19 to specific radioactivities ranging between 500 and 1,000 cpm/ng.
Platelet Aggregation, Shape Change, and the Release Reaction
Platelet aggregation was measured in an Elvi aggregometer (Elvi-Logos, Milan, 1taly).l4 Fibrinogen (0.4 mg/mL) was added to washed platelet suspensions except when thrombin was used as agonist. Platelet shape change induced by 1 pmol/L ADP was studied in the aggregometer using citrated PRP to which EDTA (5 mmol/L) had been added to prevent platelet aggregation. Decrease in oscillations of the basal tracings and increase in optical density were interpreted as being caused by platelet shape change. In some experiments the inhibitory effect of increasing concentrations of ATP (0.01 pmol/L to 10 mmol/L) on 1 pmol/L ADPinduced platelet shape change was tested. The release of I4C-serotonin (I4C-SHT) from prelabeled platelets was measured as described.I4
Clot Retraction
Glass tubes (45 x 12 mm) were weighed and placed in a water bath at 37°C. Citrated PRP (900 pL) was added to each tube and warmed at 37°C for 5 minutes. Then, 100 FL of thrombin (5 U/mL) or 90 pL of reptilase plus 10 pL of epinephrine (5 pmol/L), ADP (5 pmol/L), or Tyrode was added. At the concentration used in this study, reptilase clotted normal citrated plasma in 24 to 28 seconds. A nickel wire with a terminal loop was placed in each tube, and the stop watch started. After 1 hour of incubation, the tubes were inspected to determine if clot retraction had occurred, then the wire was gently pulled out, bringing the attached clot. After wiping their outer surface, the tubes were weighed, and the amount of serum remaining in the tubes was calculated after subtraction of the weight of the empty tubes. The percent serum remaining was calculated taking as 100% the weight of 900 p L PRP to which 100 pL Tyrode had been added.
lZSI-Labeled Fibrinogen and vWF Binding
To 165 pL of untreated washed platelet suspension incubated at 37"C, 10 pL of ADP (10 pmol/L), U46619 (1 pmol/L), or thrombin (0.01 and 1 U/mL) was added in the presence or absence of apyrase (40 pL/mL). After 1 minute of incubation at 37°C without stirring, hirudin (0.05 or 5 U/mL) was added to block further effects of thrombin (an equal volume of Tyrode was added to samples stimulated with ADP or U46619). Then, 10 p L of IZI-fibrinogen (SO pg/mL) or lxI-vWF (10 pg/mL) was added. When chymotrypsin-treated platelets were used, lzI-fibrinogen was added without previous stimulation of the platelets. The final volume was adjusted to 200 pL with Tyrode. After a 30-minute incubation at 37°C without stirring, aliquots of 50 p L were sampled in triplicate and platelet-bound ligand was separated from free ligand by centrifugation through 20% sucrose in Tyrode buffer. The radioactivity in the platelet pellet was measured in a gamma counter (LKB 1260, Bromma, Sweden). The specific binding of 1251-fibrinogen and IZ5I-vWF was calculated after subtracting the radioactivity associated with unstimulated platelets. 
1251-10E5 Binding
Twenty microliters of increasing concentrations of 1251-10E5 (2 to 20 pg/mL) were incubated with 180 pL of washed platelet suspension at 3 7 T for 1 hour. Aliquots (50 pL) were then sampled in triplicate, and platelet-bound ligand was separated from free ligand through 20% sucrose in Tyrode buffer. The radioactivity in the pellet was measured. The data were plotted according to Klotz."
12jI-7E3 Binding
Platelet suspension (500 pL) was incubated with ADP (10 pmol/L), U46619 (1 pmol/L), thrombin (1 U/mL), or Tyrode at 37°C for 15 seconds. Then, 10 pL of lZSI-7E3 was added (2 pg/mL). The final volume of the sample was 600 pL. Aliquots (50 pL) were sampled in duplicate after 2.5, 5, 10, 30, and 60 minutes of incubation, and platelet-bound ligand was separated from free ligand through 20% sucrose in Tyrode buffer. The radioactivity in the pellet was measured.
Analysis of Platelet Glycoproteins
Crossed immunoelectrophoresis and two-dimensional nonreduced, reduced sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of platelet extracts were performed as previously described.21
Measurement of Platelet Cyclic AMP (CAMP)
Platelet CAMP levels were measured by radioimmunoassay, using a commercially available kit (Amersham). Platelet CAMP was extracted essentially as described by Remuzzi et a1J2 One milliliter of 5% trichloroacetic acid (TCA) was added to 1 mL of citrated PRP after 2 minutes of incubation at 37°C with Tyrode, PGEl (1 pmol/L) plus Tyrode, PGEl plus ADP (5 and 10 p,mol/L), or PGEl plus epinephrine (5 pmol/L). The samples were snap-frozen in dry ice and methanol, thawed at room temperature, and then shaken at 4°C for 45 minutes. After centrifugation at 10,00$ at 4°C for 30 minutes, the supernatant was extracted three times with 5 mL of water-saturated ether, dried under a stream of nitrogen at 60"C, and stored at -20°C. Before assay, the samples were reconstituted with 0.05 mol/L Tris buffer containing 4 mmol/L EDTA.
Measurement of Cytoplasmic Concentrations of Ionized Calcium
Platelets were washed in 10 mmol/L HEPES Tyrode and incubated with 1 pmol/L of the fluorescent probe Fura 2/AM at 37°C for 45 minutes. Platelets were then washed and resuspended in HEPES Tyrode containing 1 pL/mL apyrase, at a final platelet count of 1 X lO"/L. Fluorescence measurements were performed at 37°C in an Aminco-Bowman spectrophotofluorometer (Silver Spring, MD), according to the method of Pollock et al?3
14C-ADP Binding to Washed Platelets
The binding of 14C-ADP to washed platelets was studied by the ultrafiltration technique described by Lips et al," with some modifications. Briefly, 80 pL of 14C-ADP (2.34 to 150 pmol/L) was added to 720 pL of washed platelet suspension, and the tubes were incubated at 37°C for 10 minutes. Samples (250 pL) in triplicate were filtered over 0.80 pm Millipore filters by vacuum aspiration. The filters were washed twice with 6 mL of saline and transferred to scintillation vials containing 1 mL of ethylene glycol monomethyl ethyl ether (Farmitalia-Carlo Erba, Milan, Italy) to dissolve the filters. After the addition of 5 mL Emulsifier Scintillator (Packard, Downers Grove, IL), the radioactivity was measured in a Beckman LS 1800 scintillation spectrometer (Brea, CA).
[2-3H]ADP Binding to Formalin-Fixed Platelets
Binding studies were performed according to the method described by Jefferson et all6 with slight modifications. [2-3H]ADP was added at a concentration of 10 nmol/L to triplicate samples of formalin-ked platelets together with increasing concentrations of unlabeled ADP (1 nmol/L to 1 mmol/L). The final volume of the samples was 200 )IL and the fiqal platelet count was 2.5 x IO"/L. After 60 minutes of incubation at room temperature, 100 )IL was centrifuged through 400 pL 20% sucrose in Tyrode buffer in an Eppendorf microcentrifuge at 12,000 rpm for 2 minutes to separate platelet-bound ligand from free ligand. The supernatant and sucrose were removed by aspiration and discarded. The tip of the plastic tubes containing the platelet pellet was cut with a razor blade and the platelets were solubilized in a glass scintillatipn vial containing 0.5 mL NCS at 50°C for 12 hours. After the addition of 10 mL OCS, the radioactivity bound to the pellet was determined.
Data from competition binding experiments were analyzed by computer program (LIGAND).z Nonspecific binding was treated as a parameter subject to error and was fit simultaneously with other parametersL6
RESULTS
Platelet Aggregation and the Release Reaction
ADP, at concentrations ranging from 2 to 100 pmol/L, induced a small and reversible wave of platelet aggregation in patient's PRP. This aggregation was much lower than that of normal PRP stimulated with the same concentrations of ADP, even when the TxAz-dependent secondary aggregation and the release reaction were inhibited in vitro by 20 kmol/L indomethacin (Fig 1) . The aggregation induced by epinephrine (5 kmol/L) was monophasic, and that induced by PAF-acether (0.2 to 2 pmol/L) or U46619 (1 kmol/L) was reversible (Fig 2) . Collagen, at a concentration of 1 p,g/mL, induced the platelets to aggregate to a small extent, whereas at a concentration of 20 kg/mL it caused extensive aggregation Citrated PRP. (Fig 2) . Arachidonic acid induced no platelet aggregation at concentrations lower than 1 mmol/L, whereas at 2 mmol/L it induced reversible platelet aggregation (not shown). The release of 14C-serotonin was impaired with all agonists tested, except for 20 p,g/mL collagen ( Table 1) . Washed platelet suspensions. The aggregation of patient's washed platelets induced by 10 to 100 p,mol/L ADP in the presence of 0.4 mg/mL fibrinogen was barely detectable (Fig 3) . Results similar to those obtained in citrated PRP were obtained in washed platelet suspensions with the other aggregating agents (not shown). Thrombin induced very slight platelet aggregation and release of 14C-serotonin at 0.01 U/mL, whereas aggregation and Control P a t i e n t 100 + i r For personal use only. on October 25, 2017. by guest www.bloodjournal.org From release caused by 1 U/mL were similar to those observed with control platelets ( Table 2) . Chymotrypsin-treated platelets from the patient aggregated to the same extent as chymotrypsin-treated platelets from controls on exposure to purified fibrinogen (0.4 mg/mL), in the absence of aggregating agents (not shown). 27 Washed normal platelets aggregated to the same extent with all agonists whether they were resuspended in autologous or in patient citrated platelet-poor plasma (PPP). The defect of aggregation of washed platelets from the patient was not corrected by suspending the platelets in citrated PPP from control subjects (not shown).
Effect of apyrase or CP/CPKplus ATP on platelet aggregation and the release reaction. Apyrase (40 pL/mL) or CP (4 mmol/L) CPK (10 U/mL) plus 1 mmol/L ATP inhibited platelet aggregation and the release reaction induced by 10 pmol/L ADP in citrated PRP and suspensions of washed platelets prepared from the blood of healthy subjects. The ADP scavengers partially inhibited platelet aggregation and the release reaction induced by other agonists in (Fig 4) and washed platelet suspensions from healthy subjects, except when high concentrations of collagen (20 pg/mL) or thrombin (1 U/mL) were used. The extent of aggregation of normal platelets under these experimental conditions was similar to that of patient's platelets (Fig 4) . The percent release of 14C-serotonin from control platelets in the presence of CP/CPK plus ATP or apyrase was similar to that obtained with the patient's platelets. Apyrase or CP/CPK plus ATP did not further inhibit aggregation or the release reaction from patient's PRP or washed platelet suspensions. Therefore, in the presence of ADP scavengers, the extent of platelet aggregation and the release reaction of patient's platelets was similar to that of normal platelets.
Because the defect of patient's platelets could be mimicked by the in vitro addition of ADP scavengers to normal platelets, we tested the hypothesis that the patient's platelets or leukocytes (which may contaminate PRP or platelet suspensions) had increased ADPase activity. Two experimental approaches were chosen. In the first series of experiments, 1 mL of unstirred patient's or normal PRP was incubated with 10 pmol/L ADP and 20 pmol/L indomethacin at 37°C for 5 minutes. The sample was then centrifuged in an Eppendorf centrifuge for 2 minutes to obtain PPP. Patient's or normal PPP (50 pL) was then added to 200 pL of patient's or normal PRP, which was stirred in the aggregometer at 1,000 rpm at 37°C. Normal and patient's PPP induced the same degree of platelet aggregation in normal PRP and only caused platelet shape change in patient's PRP. Both shape change and aggregation were completely inhibited by CP/CPK plus 1 mmol/L ATP. In a second series of experiments, platelet aggregation was studied in citrated PRP containing 20 pmol/L indomethacin, using ADP-P-S, a structural analogue of ADP that activates platelets, but is not metabolized by ADPases2* The median (range) increase in light transmission induced by ADP-P-S in the PRP of 10 normal 
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volunteers was 13% (6.5% to 22%) at 10 pmol/L and 22.8% (13.5% to 27%) at 20 pmol/L. In contrast, the increase in light transmission through the patient's PRP was 0 at 10 pmol/L and 3.4% at 20 pmol/L ADP-p-S. Apyrase (40 pL/mL) did not significantly inhibit platelet aggregation induced by ADP-P-S.
Binding of 1251-Fibrinogen and 1251-v WF
Patient's platelets bound very little 1251-fibrinogen or 12SI-~WF when stimulated with ADP (10 to 100 pmol/L). They bound much less lZ51-fibrinogen or 1251-vWF than normal platelets when stimulated with thrombin (0.01 or 1 LJ/mL) or 1 pmol/L U46619 (Table 3) . Apyrase (40 pL/mL) markedly inhibited the binding of 1251-fibrinogen and lZ5I-vWF to thrombin-or U46619-stimulated normal platelets, but did not further reduce the binding of lZ51-fibrinogen and lZ5I-vWF to patient's platelets. In the presence of apyrase, thrombin-or U46619-stimulated platelets from the patient and from control subjects bound similar amounts of 1251-fibrinogen and 1251-~WF. Chymotrypsintreated platelets from the patient and controls bound similar amounts of lz5I-fibrinogen.
Binding of 12jI-Labeled Anti-GPIIblIIIa MoAbs
Patient's platelets had 50,000 binding sites for the lz5I-labeled anti-GPIIb/IIIa MoAb 10E5, with an apparent kd of 13 nmol/L; control platelets had 46,000 binding sites per platelet, with an apparent kd of 14 nmol/L. These values are within the described normal range. 29 The anti-GPIIb/IIIa MoAb 7E3 binds at a faster rate to stimulated platelets than to resting platelet^.^" The rate of lZ51-7E3 binding to patient's platelets was increased by thrombin (1 U/mL) or U46619 (1 pmol/L), but not by ADP (10 pmol/L), whereas the three agonists similarly increased the rate of lZ51-7E3 binding to normal platelets (Fig 5) . 
Analysis of Platelet Glycoproteins
The patient's major platelet glycoproteins (Ib, IIb, IIIa, IV) were present in normal amounts, compared with controls, when studied on two-dimensional nonreduced, reduced SDS-PAGE that were subsequently silver stained. In addition, CIE experiments using a 1251-labeled antiGPIIb/IIIa MoAb (LYP2)z1 in the intermediate gel showed normal levels of the GPIIb/IIIa complex in the patient's platelets. Dissociation of the GPIlb/IIIa complex of the patient's platelets in the presence of EDTA at a basic pH was also normal compared with controls (data not shown).
Clot Retraction
When thrombin ( 5 U/mL) was added to patient's and normal PRP, fibrin formation occurred, and after a 1-hour incubation at 37°C clot retraction was complete (Table 4) . When fibrin formation was induced by reptilase (which does not activate platelets), clot retraction did not occur in normal PRP unless ADP (5 pmol/L) or epinephrine (5 For personal use only. on October 25, 2017 . by guest www.bloodjournal.org From pmol/L) had been added. In contrast, clot retraction was observed only if epinephrine (5 pmol/L) was added to patient's PRP with reptilase, ADP (5 pmol/L) having no effect.
Platelet Shape Change Induced by ADP and Its Inhibition by ATP
Patient's platelets in citrated PRP, to which 5 mmol/L EDTA had been added to prevent platelet aggregation, underwent shape change when stimulated with ADP (1 pmol/L). However, in experiments with increasing concentrations of ATP (0.01 pmol/L to 1 mmol/L), lower concentrations of ATP were needed to inhibit the ADP-induced shape change of patient's platelets (inhibitory concentration [ICso], 27 and 23 pmol/L in two different experiments) than to inhibit that of platelets from 18 healthy volunteers (ICso, 88 t 24 mean t SD, observed range 50 to 155 pmol/ L) .
Inhibition of PGEI-Induced Increase in Platelet CAMP
The basal levels of cAMP in patient's platelets were similar to those of five healthy volunteers, and they increased to a similar extent as control platelets after stimulation with PGEl (1 pmol/L) ( Table 5 ). This PGEl-induced increase in platelet CAMP was almost completely prevented in normal platelets by ADP (5 and 10 pmol/L) or epinephrine (5 pmol/L), whereas only epinephrine, but not ADP, prevented the PGEl-induced increase in cAMP concentration of patient's platelets. [Ca2+]i was lower in patient's platelets (640 and 413 nmol/L) than in control platelets (1,065 t 60).
Agonist-Stimulated Increase in Platelet Cytoplasmic
Binding of Radiolabeled ADP
Two binding systems for 14C-ADP were found in washed platelets, as described by Lips et aIz4: a saturable system mainly operating at low ADP concentrations (high-affinity system) and a second system that was not saturated at 150 pmol/L. The kd and the number of binding sites in the high affinity system were derived according to Scatchard?l The patient's platelets had 46,000 and 50,000 binding sites (data from two separate experiments), with an apparent kd of 3.1 and 3.5 pmol/L; the median (range) number of binding sites and kd value of platelets from eight normal volunteers were 65,000 (40,000 to 83,000) and 3.1 (2.7 to 3.6 pmol/L). All these values are within the described normal range.z4
However, when [2-3H]-ADP binding to formalin-fixed platelets was studied, it was found that the number of highand low-affinity binding sites for [2-3H]-ADP was markedly lower in the patient's platelets than in those from eight healthy volunteers (Table 6 ).
DISCUSSION
In this study we describe, for the first time, a new congenital defect of platelet function, characterized by impaired platelet aggregation, release reaction, and fibrinogen and vWF binding in response to several agonists in the absence of quantitative or qualitative abnormalities of the GPIIb/IIIa complex or of increased platelet cAMP concentration. This platelet function defect is probably transmitted as a recessive trait because the parents of the propositus (who could not be studied) were first cousins and his brother and sister were phenotypically normal.
Several lines of evidence indicate that the platelet function defect is caused by selective impairment of platelet responses to ADP: (1) platelet aggregation and fibrinogen and vWF binding induced by exogenous ADP is markedly defective; (2) platelet aggregation, the release reaction, and fibrinogen and vWF binding induced by agonists that cause the release of platelet granule contents, including ADP, are partially defective and are not further inhibited by ADP scavengers, which, in contrast, partially inhibit these responses in normal platelets; (3) the extent of platelet aggregation, the release reaction, and fibrinogen or vWF binding induced by release-inducing agents in the presence of ADP scavengers is similar in patient's and normal platelets; (4) the binding of the anti-GPIIb/IIIa MoAb 7E3
